CaMKII as a regulator of diabetic retinopathy
CaMKII 作为糖尿病视网膜病变的调节因子
基本信息
- 批准号:9468258
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-01-01 至 2017-09-30
- 项目状态:已结题
- 来源:
- 关键词:AdultApoptosisBackground Diabetic RetinopathyBasement membraneBlindnessBlood VesselsBlood capillariesCalmodulinCaringCharacteristicsClinicalDataDevelopmentDiabetes MellitusDiabetic RetinopathyDiagnosisDiseaseDisease ProgressionEarly DiagnosisEarly treatmentEndothelial CellsEndotheliumExtravasationFunctional disorderGlucoseGoalsHealth Care CostsHealthcareHealthcare SystemsHumanHyperglycemiaImaging TechniquesIn VitroInjuryInsulin-Dependent Diabetes MellitusKnowledgeMediatingMedicalMissionMitochondriaMolecularMolecular TargetOutcomeOxidesPathogenesisPathologyPathway interactionsPatientsPermeabilityPharmacologyPhenotypePhosphotransferasesPlayProductionPublishingReactive Oxygen SpeciesReportingResearchRetinalRetinal DiseasesRoleSignal TransductionSteroidsStressStructureSystemTestingTransgenic MiceValidationVascular DiseasesVascular Endothelial Growth FactorsVascular EndotheliumVeteransWorkagedangiogenesisbaseburden of illnesscapillarydesignendothelial dysfunctionexperienceexperimental studyin vivoin vivo Modelinhibitor/antagonistinnovationinterestlaser photocoagulationmitochondrial dysfunctionmouse modelnovelnovel strategiesnovel therapeutic interventionoverexpressionoxidationpreventpublic health relevancestandard caretargeted treatmenttooltreatment strategy
项目摘要
DESCRIPTION (provided by applicant):
Almost 25% of the veterans that are currently receiving healthcare through the VA system carry the diagnosis of diabetes. Nearly all veterans with type 1 diabetes and >60% of veterans with type 2 develop retinopathy during the first two decades of disease, 1% will experience severe visual loss or blindness. Current therapies provide clinically meaningful improvement in only 50% of veterans. Thus, there is a critical need to identify regulators of DR, which can be targeted therapeutically and will directly benefit a large group of veterans. We hypothesize that the multifunctional Ca2+/calmodulin-dependent kinase II (CaMKII) under hyperglycemic conditions promotes the endothelial pathology characteristic for diabetic retinopathy (DR), in particular endothelial apoptosis and barrier dysfunction. Thus, CaMKII inhibition may be a potent novel approach to prevent or treat DR. The long-term goal of the Grumbach lab is to study the function of CaMKII in the vasculature, specifically CaMKII modulation as a new approach to treat vascular disease. The objective of this project is to determine whether specific CaMKII inhibition in endothelium prevents non-proliferative DR. The central hypothesis is that CaMKII inhibition decreases non-proliferative DR by preventing endothelial apoptosis and barrier dysfunction, two key phenotypes of non-proliferative DR. We will test the hypothesis in a novel in vivo mouse model in which the potent and specific endogenous CaMKII inhibitor CaMKIIN is selectively overexpressed in endothelium and dissect molecular mechanisms in vitro. The rationale for the proposed studies is that, understanding whether CaMKII regulates the phenotypic changes of non- proliferative DR in vivo and drives endothelial cells ROS-production, apoptosis and barrier function may be a critical first step towards designing a specific CaMKII inhibitor to prevent and alleviate DR. We will test our central hypothesis in two specific aims: 1) Determine the role of endothelial CaMKII on non-proliferative DR in vivo, 2): Characterize whether CaMKII controls endothelial dysfunction under high glucose conditions in vitro. In the first aim, the novel in vivo model will be used to test whether CaMKII inhibition wil preserve retinal microvascular structure and function in non-proliferative DR. Under aim 2, we will define the mechanisms through which CaMKII is activated under hyperglycemia and regulates barrier function, apoptosis and ROS production in vitro. The approach is innovative because of its use of novel in vivo models and imaging techniques and specific tools to dissect CaMKII signaling. The proposed research is significant because it is expected to advance the field by defining CaMKII as a novel molecular target that controls endothelial phenotypes in DR. Ultimately, such knowledge may allow for the development of new therapeutic strategies in DR that will benefits our veterans.
描述(由申请人提供):
目前通过 VA 系统接受医疗保健的退伍军人中,近 25% 被诊断患有糖尿病。几乎所有患有 1 型糖尿病的退伍军人和 > 60% 患有 2 型糖尿病的退伍军人在患病的前 20 年都会出现视网膜病变,其中 1% 的人会出现严重的视力丧失或失明。目前的疗法仅对 50% 的退伍军人提供了具有临床意义的改善。因此,迫切需要确定 DR 的调节因子,这些调节因子可以作为治疗目标,并直接使一大批退伍军人受益。我们假设高血糖条件下多功能 Ca2+/钙调蛋白依赖性激酶 II (CaMKII) 会促进糖尿病视网膜病变 (DR) 的内皮病理特征,特别是内皮细胞凋亡和屏障功能障碍。因此,CaMKII 抑制可能是预防或治疗 DR 的有效新方法。 Grumbach 实验室的长期目标是研究 CaMKII 在脉管系统中的功能,特别是 CaMKII 调节作为治疗血管疾病的新方法。该项目的目的是确定内皮细胞中的特异性 CaMKII 抑制是否可以预防非增殖性 DR。中心假设是 CaMKII 抑制通过防止内皮细胞凋亡和屏障功能障碍(非增殖性 DR 的两个关键表型)来减少非增殖性 DR。我们将在一种新型体内小鼠模型中检验这一假设,其中有效且特异性的内源性 CaMKII 抑制剂 CaMKIIN 在内皮细胞中选择性过表达,并在体外剖析分子机制。拟议研究的基本原理是,了解 CaMKII 是否在体内调节非增殖性 DR 的表型变化并驱动内皮细胞 ROS 产生、凋亡和屏障功能可能是设计特异性 CaMKII 抑制剂以预防和缓解 DR 的关键第一步。我们将在两个具体目标中测试我们的中心假设:1)确定内皮 CaMKII 在体内非增殖性 DR 中的作用,2):表征 CaMKII 是否在体外高葡萄糖条件下控制内皮功能障碍。第一个目标是,新的体内模型将用于测试 CaMKII 抑制是否会保留非增殖性 DR 中的视网膜微血管结构和功能。在目标 2 下,我们将定义 CaMKII 在高血糖下被激活并在体外调节屏障功能、细胞凋亡和 ROS 产生的机制。该方法具有创新性,因为它使用了新颖的体内模型和成像技术以及特定工具来剖析 CaMKII 信号传导。拟议的研究意义重大,因为它有望通过将 CaMKII 定义为控制 DR 内皮表型的新型分子靶点来推进该领域的发展。最终,这些知识可能有助于开发新的 DR 治疗策略,这将使我们的退伍军人受益。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Isabella Maria Grumbach其他文献
Isabella Maria Grumbach的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Isabella Maria Grumbach', 18)}}的其他基金
Leveraging the mitochondrial regulator MIRO1 to prevent neointimal hyperplasia
利用线粒体调节剂 MIRO1 预防新内膜增生
- 批准号:
10531906 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Leveraging the mitochondrial regulator MIRO1 to prevent neointimal hyperplasia
利用线粒体调节剂 MIRO1 预防新内膜增生
- 批准号:
10384519 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Laser speckle flowgraphy as early indicator of microvasculopathy in radiation-induced vision loss
激光散斑血流成像作为辐射引起的视力丧失中微血管病变的早期指标
- 批准号:
10160909 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Laser speckle flowgraphy as early indicator of microvasculopathy in radiation-induced vision loss
激光散斑血流成像作为辐射引起的视力丧失中微血管病变的早期指标
- 批准号:
10397594 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Laser speckle flowgraphy as early indicator of microvasculopathy in radiation-induced cognitive decline
激光散斑血流成像作为辐射引起的认知衰退中微血管病变的早期指标
- 批准号:
10282945 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Laser speckle flowgraphy as early indicator of microvasculopathy in radiation-induced vision loss
激光散斑血流成像作为辐射引起的视力丧失中微血管病变的早期指标
- 批准号:
10615636 - 财政年份:2020
- 资助金额:
-- - 项目类别:
CaMKII as a regulator of diabetic retinopathy
CaMKII 作为糖尿病视网膜病变的调节因子
- 批准号:
8820648 - 财政年份:2015
- 资助金额:
-- - 项目类别:
CaMKII as a regulator of diabetic retinopathy
CaMKII 作为糖尿病视网膜病变的调节因子
- 批准号:
8996072 - 财政年份:2015
- 资助金额:
-- - 项目类别:
CaMKII regulates key mechanisms of vascular response to injury in vivo
CaMKII 调节体内血管损伤反应的关键机制
- 批准号:
8459392 - 财政年份:2012
- 资助金额:
-- - 项目类别:
CaMKII regulates key mechanisms of vascular response to injury in vivo
CaMKII 调节体内血管损伤反应的关键机制
- 批准号:
9029343 - 财政年份:2012
- 资助金额:
-- - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
- 批准号:
10585802 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
- 批准号:
10719415 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10605856 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
- 批准号:
23K08773 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
- 批准号:
23K15866 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10743485 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
- 批准号:
10749797 - 财政年份:2023
- 资助金额:
-- - 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
- 批准号:
22K09076 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
- 批准号:
10583516 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
- 批准号:
RGPIN-2019-05371 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Discovery Grants Program - Individual